Cantex's once daily, orally administered, azeliragon inhibits interactions of the receptor for advanced glycation end products (RAGE)
Researchers showed RAGE inhibition to be a potential target for treatment of triple-negative breast cancer suppressing tumor progression and metastasis
Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, today announced the publication in the peer-reviewed journal, npj Breast Cancer, a Nature Portfolio journal published in partnership with Breast Cancer Research Foundation, with results from in vitro and in vivo models for triple-negative breast cancer showing suppression of metastasis and tumor progression by RAGE inhibition. Cantex's azeliragon, currently in phase 2/3 development for the treatment of major cancers, complications of cancer treatment, and the treatment of other life-threatening illnesses, is a RAGE inhibitor that is orally administered and taken once daily.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.